Apolipoprotein AI (Apo AI), constituting 75% of HDL-associated apolipoproteins, is critical for reverse cholesterol transport (RCT), mediating cholesterol efflux from peripheral tissues to the liver. As the primary structural component of HDL, Apo AI stabilizes discoidal HDL particles, activates lecithin-cholesterol acyltransferase (LCAT) to esterify cholesterol, and facilitates HDL maturation. Its anti-inflammatory properties include blocking T-cell–monocyte interactions, reducing TNF-α and IL-1β production, and neutralizing oxidized LDL. Normal plasma levels range from 90–130 mg/100 mL, with concentrations inversely correlating with coronary heart disease (CHD) risk.
Deficiencies in Apo AI underlie Tangier disease, characterized by near-absent HDL, cholesterol-laden macrophages, and premature atherosclerosis. Mutations like APOA1 p.Leu202Arg cause systemic amyloidosis, leading to cardiac and renal dysfunction. Reduced Apo AI levels also associate with insulin resistance, impaired β-cell function, and diabetes progression. Conversely, Apo AI overexpression enhances macrophage-specific RCT, attenuating atherosclerosis.
Common uses include IVD standards, calibrators, and controls, lipid metabolism studies, biotherapeutic studies, cell based assays.
Product is discontinued. Please see the Product Change Notice. Apolipoprotein AI remains available in Standard and Immunogen Grades.
Not a hazardous substance or mixture.
12 - Non Combustible Liquids